XARELTO INTERNAL BLEEDING
CASE UPDATE: $775 MILLION DOLLAR SETTLEMENT ANNOUNCED
March 2019 - A $775 million dollar settlement was announced by Bayer and Janssen Pharmaceuticals, a division of Johnson & Johnson. The deal will settle about 25,000 lawsuits alleging Xarelto caused internal bleeding risks and the manufacturer failed to warn about the risks.
Xarelto, a prescription medication approved in 2011 to reduce the risk of blood clots in people with atrial fibrillation or irregular heartbeats, has found itself amid a growing number of complaints involving serious health risks and injuries associated with the drug. After only a few years since its approval, people are reporting severe bleeding problems while on Xarelto. If you or a loved one experienced severe bleeding problems, hemorrhage or other injuries while taking Xarelto, call our firm for a free case review at 1.888.213.0761.
Xarelto, like Pradaxa, was brought onto the market as a competitor of Warfarin. Although Warfarin requires regular monitoring and tests to avoid dangerous side effects, it is a much cheaper alternative for patients. Xarelto was developed by Johnson & Johnson, Janssen Pharmaceuticals and Bayer Health Care, and promoted as a preferable substitute that required far less monitoring than Warfarin. However, unlike Warfarin which can be reserved with Vitamin K, Xarelto lacks an effective reversal agent to stop bleeding problems that may develop, making it difficult for doctors to control bleeding in emergency situations.
XARELTO BLEEDING PROBLEMS
Our firm is investigating claims on behalf of people who may have incurred significant medical expenses or experienced wage loss and other losses because of injuries resulting from the use of Xarelto. Xarelto side effects may include:
Death from bleeding
News reports show Johnson & Johnson, Janssen Pharmaceuticals and Bayer may have experienced some difficulties in approving the lucrative Xarelto for alternate uses over the past few years. Xarelto was originally approved in July 2011 to reduce the risk of blood clots that could lead to stroke or pulmonary embolism in patients recovering from hip or knee replacement surgery. In November 2011, Xarelto was approved to reduce the risk of stroke and prevent blood clots in patients with atrial fibrillation or irregular heartbeats, not caused by a heart valve problem. The FDA has rejected efforts to expand the drug for wider uses.
FREE CASE EVALUATION
HOW WE CAN HELP
UPDATE: Following a $775 million global settlement announced in March 2019, FrancoLaw, PLLC is no longer accepting new Xarelto cases. This page is provided for informational purposes only.